Amgen Inc. (AMGN) Stock: Price, Forecast & Analyst Target
Amgen Inc. (AMGN) — MoonshotScore 84/100 (Exceptional band), calculated Nov 18, 2026. Price $443.89 (-3.07%), as of the Nov 18, 2026 trading session; market cap $240B. Expected results Feb 2, 2027.
Educational signal · not a buy or sell recommendation · How to read this
Amgen Inc. · AMGN · NASDAQ · Healthcare · Drug Manufacturers - General
Research dated 2026-09-12: Amgen is a commercial biotechnology company whose medicines span inflammation, bone health, cardiovascular disease, oncology, hematology, nephrology and neuroscience. The case hinges on whether portfolio growth and cash generation can support heavy debt and the manufacturing build for MariTide without eroding the economics of the established franchise.
Price as of Nov 18, 2026
Key Statistics
MoonshotScore v2 · Amgen (AMGN)
ExceptionalWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Elite quality, but a full valuation; the market is already moving on it. Business Quality: Elite; Financial Safety: Okay; Valuation: Full; Growth Durability: Growing; Momentum: Surging.
- EPS beat 0 of the last 4 reports
- expected results Feb 2, 2027
- Altman Z 2.55 · Piotroski F 8
Helping: business quality, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 86 | Exceptional | |
| 84 | Exceptional | |
| 86 | Exceptional | |
| 86 | Exceptional | |
| 84 | Exceptional | |
| 84 | Exceptional |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $443.89 | |
| Change on the day | -3.07% | |
| 52-week range | $312.39–$483.99 | |
| Market capitalisation | $240B | — |
| Price / earnings (trailing) | 26.35 | |
| Shares traded on the day | 2.58M | |
| Beta (volatility vs the S&P 500) | 0.42 |
Why Amgen scores 84
Share price, last 12 months +43.7%
$323.66 $465.23
What the price assumes
10.8% a year of free-cash-flow growth for ten years is what a $251.52B market value ( snapshot) asks for.
The price already assumes faster growth than the last 5 years delivered. Anything short of an acceleration leaves room to disappoint. It also runs ahead of the analysts' revenue path.
Reverse discounted cash flow: 10% discount rate, 3% growth after year ten, starting from trailing twelve months free cash flow of $9.58B. Inputs: FMP statements, estimates and quote.
How the stock reacts to earnings
EPS beat in 11 of the last 12 reports (2024–2026); the stock still fell the next session after 4 of those beats. Average first-session move: 5.7% either way.
- -8.1%Feb ’24
- +12.2%May ’24
- -3.9%Aug ’24
- +1.3%Oct ’24
- +6.6%Feb ’25
- -3.3%May ’25
- -5.7%Aug ’25
- +8.0%Nov ’25
- +6.2%Feb ’26
- -2.4%Apr ’26
- +7.6%Aug ’26
- +2.8%Nov ’26
Every report, with revenue and five-session moves
| Report | EPS | Revenue | Next session | 5 sessions |
|---|---|---|---|---|
| Beat | Beat | +2.8% | — | |
| Beat | Beat | +7.6% | +9.4% | |
| Beat | In line | -2.4% | -2.6% | |
| Beat | Beat | +6.2% | +5.8% | |
| Beat | Beat | +8.0% | +14.2% | |
| Beat | Beat | -5.7% | -5.6% | |
| Beat | Beat | -3.3% | -6.5% | |
| Beat | Beat | +6.6% | +2.7% | |
| Beat | In line | +1.3% | +1.8% | |
| In line | In line | -3.9% | -0.5% | |
| Beat | In line | +12.2% | +12.8% | |
| Beat | In line | -8.1% | -9.8% |
Beats have usually been rewarded — 7 of 11 drew a higher close the next session.
What management is saying differently
Management's own words on the Q3 FY2026 call () against Q2 FY2026 (). Analysts' questions are left out.
- New this call: “cornerstone therapy”, “cytokine release”, “first-line maintenance”, “frontline maintenance” — none of them came up in Q2 FY2026.
- Getting louder: “small cell” (6 → 12 mentions), “overall survival” (2 → 6 mentions), “serious diseases” (1 → 5 mentions).
- Gone quiet: “cardiovascular disease”, “iii clinical”, “care physicians”, “essdai score” — regular themes last call, absent this time.
- Tone: Cautious words such as “may”, “could” and “headwind” fell from 3 to 2.2 per 1,000 words, and confident words such as “record” and “strong” rose from 5 to 5.1.
Management sounded more assured than a quarter earlier — fewer hedging words, more of the confident kind.
Our track record on this stock
Since the score went from 85 to 84 while the share price moved +0.0% through .
The score has stayed in the Exceptional band across the stretch we have recorded; we grade each band change three months after it happens.
The crowd against our signals
- Analysts: 51% of 41 rate it a buy; the average target sits -6.4% from the price of $443.89.
- Last 90 days: 0 upgrades and 3 downgrades among 37 rating actions.
- Our signals: Exceptional band; strongest pillar Business Quality (93), weakest Valuation (44).
Our signals are more constructive than the crowd, led by Business Quality.
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
How to read these dates
Estimated dates can change.
Other perspectives
Council score for Amgen (AMGN): perspectives
Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
3 lenses, 3 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 20, 2026
Munger's Mindset
Balance Sheet & Valuation
Read on: Nov 19, 2026
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
One of these lenses reads this company less favourably than the MoonshotScore does: Munger lens (margin of safety). Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
The Munger lens reads the current price as overvalued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Amgen (AMGN), and what does it report?
Short answer · as of
Amgen develops, manufactures and sells prescription medicines used in specialist care, including Prolia, Repatha, Enbrel and Otezla.
Research dated 2026-09-12.
Demand ultimately comes from treated patients and prescribing decisions, while physicians, clinics, dialysis centers, hospitals and pharmacies form the commercial channel, supported by wholesale distribution.
The reported revenue line combines products with very different indications and demand patterns, so Amgen is not economically equivalent to a biotechnology company awaiting its inaugural commercial therapy. Its accounts measure an established medicine portfolio alongside substantial research, selling and administrative spending.
What do the latest results show for Amgen (AMGN)?
Research dated 2026-09-12.
The latest period delivered a marked rise in revenue, gross profit, operating profit, net income and diluted earnings from the preceding period. Revenue and earnings also cleared market estimates, extending a consistent run of results above consensus.
The financial series establishes the improvement; management’s explanation is forward-looking. Planned manufacturing investment is intended to accommodate volume growth and prepare capacity for MariTide, while the stated outlook calls for continued revenue growth and strong operating profitability.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | Not available | Not available | Not available | Not available |
| Jun 30, 2026 | Not available | Not available | Not available | Not available |
| Mar 31, 2026 | Not available | Not available | Not available | Not available |
| Dec 31, 2025 | Not available | Not available | Not available | Not available |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $10.37B Nov 3, 2026
- Latest report · revenue estimate
- $10.07B Nov 3, 2026
- Latest report · revenue vs estimate
- Above estimate Nov 3, 2026
- Latest report · EPS vs estimate
- Above estimate Nov 3, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Nov 3, 2026 | $10.37B | $10.07B | $6.4500 | $5.7900 |
| Aug 4, 2026 | $10.05B | $9.43B | $6.2900 | $5.6200 |
| Apr 30, 2026 | $8.62B | $8.58B | $5.1500 | $4.7700 |
| Feb 3, 2026 | $9.87B | $9.47B | $5.2900 | $4.7300 |
How to read these figures
Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Sep 2025 | $9.56B | $3.22B | $5.93 (diluted) |
| Q4 FY2025 | $9.87B | $1.33B | $2.45 (diluted) |
| Q1 FY2026 | $8.62B | $1.82B | $3.34 (diluted) |
| Q2 FY2026 | $10.05B | $2.38B | $4.37 (diluted) |
What are the financial strengths and risks for Amgen (AMGN)?
Short answer
Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.
Research dated 2026-09-12.
Amgen pairs high gross and operating margins with substantial operating cash generation. Cash and short-term investments have risen sharply from the recent low, and the latest operating cash inflow comfortably exceeded capital expenditure.
Debt nevertheless stands far above available cash, while leverage remains elevated. That makes sustained product cash flow especially important: weaker operating performance combined with the MariTide capacity program would reduce room for debt reduction or other capital uses. Revenue has expanded across the annual series, but net income has been much less orderly, reinforcing the distinction between commercial growth and earnings stability.
What should you watch next at Amgen (AMGN)?
Short answer · as of
The next earnings report is expected on Feb 2, 2027.
Research dated 2026-09-12.
MariTide spending is the most concrete operational checkpoint. Watch whether capital expenditure rises as planned, whether operating cash flow continues to cover that build comfortably, and whether management preserves its product-sales margin outlook while adding capacity.
The next earnings release also tests whether revenue can remain near the latest elevated level and whether Amgen can extend its run of results above expectations. Longer-range analyst estimates embed continued revenue and earnings expansion, so any widening gap between portfolio growth, cash conversion and consensus expectations would matter.
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
Checked against the records this page reads, on the dates shown above.
How does Amgen compare with its peers?
Short answer
Amgen's score ranks 5th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-12.
Amgen differs from development-stage biotechnology businesses because it already manufactures and distributes a broad portfolio of widely used medicines through established healthcare channels. Its results therefore depend on aggregate prescribing and patient demand across marketed franchises, not solely on a clinical milestone.
The biotechnology character remains visible in heavy research spending and the need to fund manufacturing before prospective demand arrives. This combination of mature commercial cash flow, continued scientific investment and meaningful leverage gives Amgen a different financial profile from a narrowly focused drug developer.
| Company | Price | Market value | Score |
|---|---|---|---|
| $1382.75 Nov 18, 2026 | $1.23T | 98 5-pillar Nov 18, 2026 | |
| $47.12 Nov 18, 2026 | $113B | 87 5-pillar Nov 18, 2026 | |
| $178.76 Nov 18, 2026 | $277B | 85 5-pillar Nov 18, 2026 | |
| $59.56 Nov 18, 2026 | $122B | 85 5-pillar Nov 18, 2026 | |
| Amgen (AMGN) — this page | $443.89 | $240B | 84 |
| $286.01 Nov 18, 2026 | $506B | 83 5-pillar Nov 18, 2026 | |
| $272.70 Nov 18, 2026 | $656B | 83 5-pillar Nov 18, 2026 | |
| $155.21 Nov 18, 2026 | $293B | 82 5-pillar Nov 18, 2026 | |
| $48.58 Nov 18, 2026 | $97.4B | 77 5-pillar Nov 18, 2026 | |
| $168.98 Nov 18, 2026 | $210B | 72 5-pillar Nov 18, 2026 | |
| $137.78 Nov 18, 2026 | $340B | 69 5-pillar Nov 18, 2026 | |
| $28.06 Nov 18, 2026 | $160B | 67 5-pillar Nov 18, 2026 | |
| $8.47 Nov 18, 2026 | $5.76B | 60 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $230.00 – $531.00
- Consensus target
- $426.29
- Median target
- $430.00
Consensus record · Captured .
Measured against a quoted price of $443.89 (as of Nov 18, 2026).
Insider activity
Form 4 records via FMP · Of the newest 500 records, those within the last 180 days, newest dated Nov 6, 2026
- Transactions
- 22
- Identified insiders
- 8
- Purchases
- 0
- Sales
- 4
- Other transactions
- 18
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held AMGN in their latest 13F filing, and what they did against the filing before it.
| Investor | Manager | 13F quarter | Portfolio weight | Value | Last quarter |
|---|---|---|---|---|---|
| Bridgewater Associates | Founded by Ray Dalio | Q3 2026 | 0.21% | $48.33M | Added +424.3% shares |
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Amgen (AMGN)?
What Investors Ask About Amgen (AMGN) — Healthcare
Research dated 2026-09-12; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
How does Amgen make money from Prolia and Repatha?
Amgen manufactures and sells these prescription medicines into healthcare channels serving prescribers and patients; treatment demand and prescribing activity feed product revenue through wholesalers and direct channels.
Why is Amgen building MariTide manufacturing capacity before launch?
Management is investing ahead of launch to prepare manufacturing capacity for expected volume growth, making capital spending and cash conversion important evidence of execution.
Can Amgen fund the MariTide build while carrying heavy debt?
Current operating cash generation covers recent capital spending comfortably, but debt substantially exceeds cash and short-term investments. Continued product cash flow is therefore central to funding capacity expansion without further constraining financial flexibility.
Why does Amgen’s product mix matter beyond Enbrel?
Amgen earns revenue across medicines including Prolia, Repatha and Otezla, while its broader portfolio reaches inflammation, bone health, cardiovascular disease, cancer care and other specialties. The business is consequently exposed to demand across a portfolio rather than Enbrel alone.
What is the AMGN stock price today?
The last price recorded for Amgen Inc. (AMGN), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the AMGN price target?
The analyst consensus price target for Amgen Inc. (AMGN), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Reviewed by Sedat ANAK, Founder and Editor-in-Chief, on 2026-11-07.
Sources: the source register lists the 42 figures on this page — 1 from SEC filings and earnings calls, 35 from Financial Modeling Prep (FMP), 3 with no recorded source, 2 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources (as of 2026-09-12), by section of the research
ETFs that hold AMGN
Funds in our ETF coverage that list AMGN among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.
